Health

  Lawyers

 

 

 

 

 

Litigation Index

Medical Info

Alzheimer's Disease

Arthritis

Asthma

Botulism

Bronchitis

Carbon Monoxide Poisoning

Chicken Pox

Cholesterol

Diabetes

Eczema

Epilepsy

Influenza (flu)

Hypoglycemia

Lyme Disease

Plantar Warts

Rocky Mountain Spotted Fever

Salmonella

Shingles

Thrush

West Nile Virus

 

 

 

 
 

    Directory of Health Related Problems and Information
 

Medical Litigation

General Health

 

Vioxx Press Release Information Sheet

 


 

 
 
 
 
 
 
 

Merck to Appeal Verdict in Texas VIOXX® Product Liability Case

WHITEHOUSE STATION, N.J., Aug. 19, 2005 - Merck & Co., Inc. is disappointed a state court jury in Brazoria County, Texas, returned a verdict in favor of the plaintiff in the VIOXX® product liability lawsuit Ernst v. Merck.  Merck will appeal the verdict.

"We believe that the plaintiff did not meet the standard set by Texas law to prove VIOXX caused Mr. Ernst's death," said Jonathan Skidmore of Fulbright & Jaworski, a member of Merck's defense team.  "There is no reliable scientific evidence that shows VIOXX causes cardiac arrhythmias, which an autopsy showed was the cause of Mr. Ernst's death, along with coronary atherosclerosis."

"This case did not call for punitive damages," added Skidmore.  "Merck acted responsibly - from researching VIOXX prior to approval in clinical trials involving almost 10,000 patients - to monitoring the medicine while it was on the market - to voluntarily withdrawing the medicine when it did."

Merck is examining various bases for appeal, including:

  • Allowing opinion testimony to be given to the jury by unqualified experts,
  • Allowing opinion testimony that was not based on a reliable scientific basis as required by Texas law,
  • Allowing evidence with no relevance to the issues of the case, which unfairly prejudiced the jury, and
  • Allowing undisclosed surprise witness and expert testimony contrary to Texas law.

"We believe that we have strong points to raise on appeal and are hopeful that the appeals process will correct the verdict," said Kenneth C. Frazier, senior vice president and general counsel of Merck.  "Our appeal is about fundamental rights to a fair trial." 

"There are other VIOXX cases coming to trial and we will vigorously defend them one by one over the coming years," Frazier added.

About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.  Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories.  The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them.  Merck also publishes unbiased health information as a not-for-profit service.  For more information, visit www.merck.com.

 

 About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.  Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories.  The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them.  Merck also publishes unbiased health information as a not-for-profit service.  For more information, visit www.merck.com.

 Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential or financial performance.  No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.  Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.

 

 

 

 

Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. Health-Lawyers.com does not represent or endorse the accuracy or reliability of any of the information, content or advertisements (collectively, the "Materials") contained on, distributed through, or linked, downloaded or accessed from any of the services contained on this web-site (the "Service"), nor the quality of any products, information or other materials displayed, purchased, or obtained by you as a result of an advertisement or any other information or offer in or in connection with the Service (the "Products"). You hereby acknowledge that any reliance upon any Materials shall be at your sole risk. Health-Lawyers.com reserves the right, in its sole discretion and without any obligation, to make improvements to, or correct any error or omissions in any portion of the Service or the Materials. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider.